Cheng et al. found that pretreatment SCC Ag >10 ng/mL was a significant poor prognostic factor of progression-free survival (PFS), locoregional recurrence-free survival, and distant metastasis-free survival in patients with stage IB-IVA cervical cancer in patients who underwent concurrent chemoradiation therapy [33]. This evidence concerns the gene SERPINB3 and cervical cancer.